Market Overview

Seoul National University Hospital to Launch Syapse Precision Medicine Platform, in Cooperation with Megazone Corporation, for the First Time in the APAC Region

Share:

Seoul National University Hospital (SNUH) recently announced that it has
successfully implemented the interface of the clinical and genomic data
in accordance with the Korean medical system and officially launched the
Syapse Precision Medicine (PM) platform for the first time in both Korea
and APAC. The contract for the adoption of Syapse platform was signed
back in early 2018.

Based on the integrated clinical/genomic data, it is now possible to
provide a software platform that provides patient-oriented and
cost-effective cancer treatment for domestic patients for the first
time, maximizing utilization of the genomic data.

Syapse is a provider of health care solutions based in San Francisco,
U.S. The company specializes in helping oncologists provide cancer
patients through improved treatment with optimized therapies. With their
mission, ‘To provide the best treatment for all cancer patients through
Precision Medicine (PM)' Syapse has implemented PM platform at 300+
hospitals located in 25 states across the U.S. The hospital has
established PM platform to provide fully optimized cancer treatment for
approximately 1 million people, 10% of the total cancer patient
population in the U.S.

In Korea, Megazone,
the country's largest AWS partner and cloud specialized company signed
an exclusive partnership agreement with Syapse earlier this year, to
assist with the adoption, deployment and operation of the PM solutions.

Megazone
is the first cloud MSP to achieve a revenue of 110 million dollars in
the Korean market last year and it has already achieved a sales revenue
of more than 112 million dollars in the H1 2018. In 2012, Megazone
signed the partnership with Amazon Web Services for the first time in
Korea and was selected as Premier Consulting Partner, the highest level
for AWS partner in 2015. Megazone is the first and only one to have
acquired ISMS, Information Security Management System certification.
Megazone is currently offering ‘Cloud One-Stop' service across the full
life cycle based on the holistic methodology, including cloud adoption,
implementation, deployment, operation, security/back-up, 24/7 support,
managed services and optimization, to more than 800 customers.

The newly-launched Syapse platform, made available through the
cooperation of the two organizations, has significance in that it's the
first case ever in APAC.

Meanwhile, SNUH successfully held the Syapse Opening Symposium at its
facility on July 13th in accordance with the launch of the
platform.

The symposium, with the theme of "Present and Future of Korea's
Precision Medicine Platform", was held on the successful adoption
experience and developments of the Syapse platform, the first cancer
treatment medical platform in Korea and APAC, with more than 300 experts
attending.

In the first session, introduction on SNUH and Syapse was made, along
with a case study in the U.S. presented. Also, the professors from the
Information Technology team, Precision Medicine center, and other
medical departments participated in discussing the six-month adoption
journey of the Syapse platform as well as the trends and future. The
second half of the event was on the examination of the present and
future of the Korean Precision Medicine platform through lectures and
panel discussions among internal and external experts.

"Syapse is a powerful platform that could help us make effective cancer
treatment decisions using genetic analysis technology. With this, SNUH
will present a new standard in the treatment of evidence-based precision
cancer and oncology" said Kyung Hwan Kim, the head of SNUH Information
Team.

"I would like to congratulate SNUH for the official launch of the first
cancer Precision Medicine platform service in Korea. As a cutting-edge
Precision Medicine solution proven in the global market, Syapse will
help SNUH medical staff make more effective decisions in cancer
treatment. I believe that this will serve as a stepping stone for
development of the Korean medical community and the reinforcement of the
medical treatment competence of cancer patients." said Max Lee, CSO of
Megazone Corporation.

View Comments and Join the Discussion!